Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

Published:2017-10-09 Issue:62 Volume:8 Page:105103-105114
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Baldacci Simon¹²,Mazieres Julien³,Tomasini Pascale⁴,Girard Nicolas⁵,Guisier Florian⁶,Audigier-Valette Clarisse⁷,Monnet Isabelle⁸,Wislez Marie⁹,Pérol Maurice¹⁰,Dô Pascal¹¹,Dansin Eric¹²,Leduc Charlotte¹³,Leprieur Etienne Giroux¹⁴,Moro-Sibilot Denis¹⁵,Tulasne David²,Kherrouche Zoulika¹²,Labreuche Julien¹⁶,Cortot Alexis B.¹²

Affiliation:

1. CHU Lille, Thoracic Oncology Department, Univ. Lille, Siric ONCOLille, Lille, France

2. Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161, M3T, Mechanisms of Tumorigenesis and Targeted Therapies, Lille, France

3. Toulouse University Hospital, Université Paul Sabatier, Toulouse, France

4. Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France

5. Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France

6. Rouen University Hospital, Thoracic oncology unit & Normandy University, IRIB, LITIS Lab, EA 4103 QuantIF team, Rouen, France

7. Service de Pneumologie, Centre Hospitalier Sainte Musse, Toulon, France

8. Centre Hospitalier Intercommunal de Créteil, Créteil, France

9. APHP Hôpital Tenon, Paris, France

10. Department of Medical Oncology, Centre Léon Bérard, Lyon, France

11. Centre Régional de Lutte Contre le Cancer François Baclesse, Caen, France

12. Centre Oscar Lambret, Lille, France

13. CHU Strasbourg, Strasbourg, France

14. APHP - Hôpital Ambroise Paré, Boulogne-Billancourt, France

15. Unité d'Oncologie Thoracique, Service de Pneumologie, CHU Grenoble-Alpes, La Tronche, France

16. EA 2694 University of Lille, Lille, France